摘要
目的观察急性冠脉综合征(acutecoronary syndrome,ACS)发生后24h内使用两种不同剂量阿托代他汀的疗效及并发症情况。方法 60例ACS患者随机分为两组,24h内分别给予阿托伐他汀20mg/d与60mg/d,用药时间1年。观察两组患者血脂变化情况、住院期间及存活出院者主要心血管事件及药物不良反应。结果两组治疗2周、3个月、6个月及12个月的血清总胆固醇及低密度脂蛋白胆固醇浓度均比治疗前明显降低,差异有统计学意义(P<0.01);且60mg/d组在各时间段的血清总胆固醇及低密度脂蛋白胆固醇浓度低于20mg/d组,差异有统计学意义(P<0.05)。住院及随访期间60mg/d组复发性心绞痛、心力衰竭、心律失常发生率均较20mg/d明显降低,差异有统计学意义(P<0.05)。两组未见严重不良反应。结论早期大剂量阿托伐他汀治疗ACS安全有效。
Objectives To observe the effects and complications of two different doses of atorvastatin in treating patients with acute coronary syndrome （ACS） in 24 h. Methods Sixty patients with ACS were randomly divided into two groups, they were treated with atorvastatin 20 mg and 60 mg a day respectively for one year. The effect of the two doses of atorvastatin on regulating lipid, incidence of cardiocerebral vascular events and survival while in hospital and side effect of atorvastatin were observed. Results The serum concentrations of total cholesterol （TC） and low density lipoprotein-cholesterol （LDL-C） were significantly decreased, as compared with base levels in both groups after 2 weeks, 3 months, 6 months and 12 months, and the differences were significantly（P〈0.01 ）. But the effect of regulating lipid in 60 mg atorvastatin group was superior to that of 20 mg atorvastatin group in every time segments, and the differences were significant （P〈0.05）. In 60 mg group, incidence of cardiocerebral vascular events such as recurrent angina pectoris, heart failure, arrhythmia were lower than those of 10 mg group during hospitalization and 12-month＇s follow-up period. There were no serious adverse events in two groups. Conclusions Early larger dose atorvastatin treatment of patients with ACS is safe and effective.
出处
《岭南心血管病杂志》
2011年第1期24-26,共3页
South China Journal of Cardiovascular Diseases
